Daporinad - TopoTarget Switzerland
Alternative Names: APO866; FK 866; NMPRTsLatest Information Update: 14 Mar 2023
At a glance
- Originator Astellas Pharma GmbH
- Developer TopoTarget Switzerland
- Class Acrylamides; Antineoplastics; Piperidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Malignant melanoma
Most Recent Events
- 21 Apr 2018 Pharmacodynamics data from a preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 27 Jul 2015 No recent reports of development identified - Phase-II for Cutaneous T-cell lymphoma in the European Union and Switzerland (IV)
- 02 Jun 2015 TopoTarget terminates a phase-II trial in Cutaneous T-cell lymphoma in European Union and Switzerland due to lack of efficacy (NCT00431912)